Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Journal of the National Cancer Institute, 01/24/2012Eisen T et al.
The authors identify and summarize clear recommendations for the management of dermatologic, gastrointestinal, thyroid, cardiovascular, and other adverse events (AEs), based predominantly on expert opinion. However, because the evidence for the suggested management strategies is largely anecdotal, there is a need for further systematic investigation of management strategies for AEs related to targeted therapies for renal cell carcinoma (RCC).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.